Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

152 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pregnancy and fetal outcomes after interferon-β exposure in multiple sclerosis.
Amato MP, Portaccio E, Ghezzi A, Hakiki B, Zipoli V, Martinelli V, Moiola L, Patti F, La Mantia L, Mancardi GL, Solaro C, Tola MR, Pozzilli C, De Giglio L, Totaro R, Lugaresi A, Di Tommaso V, Paolicelli D, Marrosu MG, Comi G, Pellegrini F, Trojano M; MS Study Group of the Italian Neurological Society. Amato MP, et al. Among authors: tola mr. Neurology. 2010 Nov 16;75(20):1794-802. doi: 10.1212/WNL.0b013e3181fd62bb. Neurology. 2010. PMID: 21079181
Breastfeeding is not related to postpartum relapses in multiple sclerosis.
Portaccio E, Ghezzi A, Hakiki B, Martinelli V, Moiola L, Patti F, La Mantia L, Mancardi GL, Solaro C, Tola MR, Pozzilli C, De Giglio L, Totaro R, Lugaresi A, De Luca G, Paolicelli D, Marrosu MG, Comi G, Trojano M, Amato MP; MS Study Group of the Italian Neurological Society. Portaccio E, et al. Among authors: tola mr. Neurology. 2011 Jul 12;77(2):145-50. doi: 10.1212/WNL.0b013e318224afc9. Epub 2011 Jul 6. Neurology. 2011. PMID: 21734184
Changes in magnetic resonance imaging disease measures over 3 years in mildly disabled patients with relapsing-remitting multiple sclerosis receiving interferon β-1a in the COGnitive Impairment in MUltiple Sclerosis (COGIMUS) study.
Bastianello S, Giugni E, Amato MP, Tola MR, Trojano M, Galletti S, Luccichenti G, Quarantelli M, Picconi O, Patti F; COGIMUS study group. Bastianello S, et al. Among authors: tola mr. BMC Neurol. 2011 Oct 14;11:125. doi: 10.1186/1471-2377-11-125. BMC Neurol. 2011. PMID: 21999142 Free PMC article. Clinical Trial.
Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis.
Patti F, Amato MP, Bastianello S, Caniatti L, Di Monte E, Ferrazza P, Goretti B, Gallo P, Morra VB, Lo Fermo S, Picconi O, Tola MR, Trojano M; COGIMUS Study Group. Patti F, et al. Among authors: tola mr. Mult Scler. 2010 Jan;16(1):68-77. doi: 10.1177/1352458509350309. Epub 2009 Dec 7. Mult Scler. 2010. PMID: 19995846 Clinical Trial.
Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group--Italian Neurological Society.
Ghezzi A, Grimaldi LM, Marrosu MG, Pozzilli C, Comi G, Bertolotto A, Trojano M, Gallo P, Capra R, Centonze D, Millefiorini E, Sotgiu S, Brescia Morra V, Amato MP, Lugaresi A, Mancardi G, Caputo D, Montanari E, Provinciali L, Durelli L, Bergamaschi R, Bellantonio P, Tola MR, Cottone S, Savettieri G, Tedeschi G; MS-SIN Study Group. Ghezzi A, et al. Among authors: tola mr. Neurol Sci. 2011 Apr;32(2):351-8. doi: 10.1007/s10072-010-0469-0. Neurol Sci. 2011. PMID: 21234775
Quality of life, depression and fatigue in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: 3-year results from the COGIMUS (COGnitive Impairment in MUltiple Sclerosis) study.
Patti F, Amato MP, Trojano M, Bastianello S, Tola MR, Picconi O, Cilia S, Cottone S, Centonze D, Gasperini C; COGIMUS Study Group. Patti F, et al. Among authors: tola mr. Mult Scler. 2011 Aug;17(8):991-1001. doi: 10.1177/1352458511401943. Epub 2011 Apr 18. Mult Scler. 2011. PMID: 21502310 Clinical Trial.
Patient adherence to and tolerability of self-administered interferon β-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study.
Lugaresi A, Florio C, Brescia-Morra V, Cottone S, Bellantonio P, Clerico M, Centonze D, Uccelli A, di Ioia M, De Luca G, Marcellusi A, Paolillo A; BRIDGE study group. Lugaresi A, et al. BMC Neurol. 2012 Mar 5;12:7. doi: 10.1186/1471-2377-12-7. BMC Neurol. 2012. PMID: 22390218 Free PMC article. Clinical Trial.
Endovascular treatment of CCSVI in patients with multiple sclerosis: clinical outcome of 462 cases.
Ghezzi A, Annovazzi P, Cocco E, Coarelli G, Lugaresi A, Rovaris M, Patti F, Capello E, Rodegher ME, Moiola L, Malucchi S, Salemi G, De Rossi N, Provinciali L, Perini P, Bergamaschi R, Scarpini E, Lus G, Gallo A, Tola MR, Amato MP, Rottoli MR, Bianchi A, Comi G; MS Study Group-Italian Society of Neurology. Ghezzi A, et al. Among authors: tola mr. Neurol Sci. 2013 Sep;34(9):1633-7. doi: 10.1007/s10072-013-1300-5. Epub 2013 Jan 25. Neurol Sci. 2013. PMID: 23354606
Subcutaneous interferon β-1a may protect against cognitive impairment in patients with relapsing-remitting multiple sclerosis: 5-year follow-up of the COGIMUS study.
Patti F, Morra VB, Amato MP, Trojano M, Bastianello S, Tola MR, Cottone S, Plant A, Picconi O; COGIMUS Study Group. Patti F, et al. Among authors: tola mr. PLoS One. 2013 Aug 30;8(8):e74111. doi: 10.1371/journal.pone.0074111. eCollection 2013. PLoS One. 2013. PMID: 24137499 Free PMC article. Clinical Trial.
152 results